William Blair Has Pessimistic Outlook of Certara Q2 Earnings

Certara, Inc. (NASDAQ:CERT) – Equities research analysts at William Blair decreased their Q2 2025 earnings per share estimates for Certara in a note issued to investors on Thursday, February 27th. William Blair analyst M. Smock now forecasts that the company will earn $0.06 per share for the quarter, down from their previous estimate of $0.07. William Blair has a “Market Perform” rating on the stock. The consensus estimate for Certara’s current full-year earnings is $0.28 per share. William Blair also issued estimates for Certara’s Q1 2026 earnings at $0.08 EPS, Q2 2026 earnings at $0.07 EPS, Q3 2026 earnings at $0.10 EPS and Q4 2026 earnings at $0.07 EPS.

Other equities research analysts have also recently issued reports about the stock. Barclays upped their target price on shares of Certara from $12.00 to $13.00 and gave the company an “equal weight” rating in a report on Friday, February 28th. Robert W. Baird cut their price objective on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research report on Tuesday, November 5th. Stephens reissued an “overweight” rating and set a $17.00 target price on shares of Certara in a report on Thursday, February 27th. Finally, TD Cowen started coverage on Certara in a report on Thursday, February 27th. They set a “buy” rating and a $16.00 price target for the company. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $15.83.

Certara Trading Down 0.8 %

NASDAQ CERT opened at $11.85 on Monday. Certara has a 12 month low of $9.41 and a 12 month high of $19.87. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The stock has a 50 day moving average of $12.50 and a 200-day moving average of $11.63. The company has a market cap of $1.91 billion, a PE ratio of -59.25, a PEG ratio of 9.29 and a beta of 1.57.

Institutional Investors Weigh In On Certara

A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its holdings in Certara by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 12,437,089 shares of the company’s stock valued at $132,455,000 after purchasing an additional 38,068 shares during the period. Wasatch Advisors LP raised its position in shares of Certara by 22.4% in the third quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company’s stock valued at $105,577,000 after buying an additional 1,651,076 shares in the last quarter. ArrowMark Colorado Holdings LLC raised its holdings in Certara by 164.2% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company’s stock valued at $66,171,000 after acquiring an additional 3,861,674 shares in the last quarter. Geneva Capital Management LLC lifted its position in shares of Certara by 0.7% during the 3rd quarter. Geneva Capital Management LLC now owns 5,510,209 shares of the company’s stock valued at $64,525,000 after acquiring an additional 37,392 shares during the period. Finally, Teacher Retirement System of Texas grew its holdings in shares of Certara by 13.9% during the 4th quarter. Teacher Retirement System of Texas now owns 4,557,951 shares of the company’s stock worth $48,542,000 after purchasing an additional 557,348 shares in the last quarter. Institutional investors own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.